Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > I welcome all new investors in Kaly

<< Previous

Bullboard Posts

Next >>

Post by losingmyshirton Nov 13, 2020 1:32pm

916 Views

Post# 31896107

I welcome all new investors in Kaly

The only way that we will minimize our losses will be if others are duped into investing in Kaly the way that we were.

When I invested it was b/c of GVHD. That is off the table. Now Robert has set his sights on R107.
Another pipe dream but hey, if he can put a good spin on it and attract new money, we might be able to unload at a small loss and move on and let the new bagholders learn the hard way.
Who is going to be ready to throw money at this stock after a 5 month halt?

Bring us new Sheeple, and let Kaly handle the slaughter.

<< Previous

Bullboard Posts

Next >>

Day trading vs. swing trading strategies for small-cap stocks